| CGNAX | RBEGX | CGNAX / RBEGX | |
| Total Expense Ratio | 0.69 | 1.14 | 61% |
| Annual Report Gross Expense Ratio | 0.69 | 1.14 | 61% |
| Fund Existence | 14 years | 11 years | - |
| Gain YTD | 17.374 | 16.949 | 103% |
| Front Load | 4% | N/A | - |
| Min. Initial Investment | 250 | 250 | 100% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 21.7B | 21.7B | 100% |
| Annual Yield % from dividends | 1.56 | 1.16 | 135% |
| Returns for 1 year | 12.58 | 12.07 | 104% |
| Returns for 3 years | 46.24 | 43.42 | 106% |
| Returns for 5 years | 43.00 | 37.55 | 115% |
| Returns for 10 years | 102.12 | 76.94 | 133% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| JXI | 81.52 | 0.54 | +0.67% |
| iShares Global Utilities ETF | |||
| RSMR | 21.65 | 0.02 | +0.08% |
| FT Vest U.S. Equity Equal Weight Buffer ETF - March | |||
| SDIV | 24.34 | 0.01 | +0.04% |
| Global X SuperDividend™ ETF | |||
| JANT | 40.38 | N/A | +0.01% |
| AllianzIM US Large Cap Buffer10 Jan ETF | |||
| THNR | 24.46 | N/A | N/A |
| Amplify Weight Loss Drug & Treatment ETF | |||